See more : Modiv Inc. (MDV-PA) Income Statement Analysis – Financial Results
Complete financial analysis of Dynavax Technologies Corporation (DVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dynavax Technologies Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- The Siam Cement Public Company Limited (SCVPF) Income Statement Analysis – Financial Results
- IFIS Japan Ltd. (7833.T) Income Statement Analysis – Financial Results
- Crown ElectroKinetics Corp. (CRKN) Income Statement Analysis – Financial Results
- Wafangdian Bearing Company Limited (200706.SZ) Income Statement Analysis – Financial Results
- Sema4 Holdings Corp. (SMFR) Income Statement Analysis – Financial Results
Dynavax Technologies Corporation (DVAX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.dynavax.com
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.28M | 722.68M | 439.44M | 46.55M | 35.22M | 8.20M | 327.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.61M | 23.95M | 40.32M | 37.09M | 14.09M | 4.85M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Cost of Revenue | 50.17M | 262.15M | 173.57M | 13.91M | 19.39M | 21.80M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 182.12M | 460.53M | 265.87M | 32.64M | 15.83M | -13.60M | -867.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.32M | 22.97M | 39.34M | 36.11M | 13.09M | 4.15M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Gross Profit Ratio | 78.40% | 63.73% | 60.50% | 70.12% | 44.95% | -165.87% | -265.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.62% | 95.91% | 97.57% | 97.36% | 92.88% | 85.60% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 54.89M | 46.60M | 32.23M | 28.61M | 62.33M | 74.95M | 64.99M | 84.49M | 86.94M | 84.58M | 50.87M | 49.15M | 51.32M | 53.68M | 38.71M | 44.77M | 65.89M | 50.12M | 27.89M | 23.13M | 14.38M | 15.97M | 17.36M | 8.27M |
| General & Administrative | 152.95M | 131.41M | 100.16M | 79.26M | 48.72M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 24.76M | 26.27M | 31.76M | 7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 152.95M | 131.41M | 100.16M | 79.26M | 74.99M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 4.21M | 4.12M | 4.53M | 3.45M |
| Other Expenses | 11.31M | 7.80M | 8.66M | 6.81M | 3.35M | -70.00K | -486.00K | -2.49M | 317.00K | 433.00K | -348.00K | -293.00K | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 219.15M | 178.01M | 132.38M | 107.86M | 137.32M | 139.72M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Cost & Expenses | 269.31M | 440.16M | 305.96M | 121.77M | 156.71M | 161.52M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Interest Income | 31.99M | 7.91M | 140.00K | 1.26M | 3.37M | 3.83M | 1.34M | 755.00K | 205.00K | 191.00K | 116.00K | 291.00K | 103.00K | 85.00K | 112.00K | 1.74M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.76M | 6.73M | 11.18M | 19.06M | 16.98M | 9.34M | 0.00 | 0.00 | 572.00K | 35.00K | 0.00 | 2.35M | 1.96M | 1.65M | 124.00K | 9.16M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.28M | 6.67M | 7.01M | 9.34M | 21.53M | 14.48M | 4.44M | 2.26M | 1.37M | 1.40M | 1.33M | 1.21M | 1.60M | 2.40M | 2.84M | 2.83M | 632.00K | 1.53M | 3.13M | 3.27M | 576.00K | 678.00K | 0.00 | -2.05M |
| EBITDA | 9.67M | 307.70M | 95.71M | -46.84M | -114.09M | -135.08M | -90.72M | -110.19M | -104.86M | -89.28M | -65.39M | -66.39M | -45.04M | -53.26M | -12.17M | -21.29M | -71.09M | -60.67M | -19.36M | -15.44M | -17.19M | -17.98M | -19.53M | -11.72M |
| EBITDA Ratio | 4.16% | 41.27% | 32.38% | -144.26% | -325.87% | -1,824.36% | -27,292.05% | -1,002.51% | -2,581.51% | -822.04% | -579.16% | -695.88% | -216.57% | -154.67% | -30.45% | -70.87% | -497.32% | -1,136.60% | -132.09% | -91.73% | -2,080.87% | -1,260.06% | -827.94% | 0.00% |
| Operating Income | -37.03M | 283.52M | 134.49M | -75.22M | -121.49M | -153.32M | -96.01M | -110.71M | -105.07M | -91.31M | -66.49M | -67.60M | -47.58M | -47.59M | -15.12M | -24.12M | -71.09M | -64.98M | -22.49M | -16.86M | -17.76M | -18.66M | -19.53M | -9.66M |
| Operating Income Ratio | -15.94% | 39.23% | 30.60% | -161.59% | -344.95% | -1,870.20% | -29,359.33% | -1,002.51% | -2,594.40% | -827.69% | -590.95% | -695.86% | -220.12% | -198.70% | -37.49% | -65.02% | -504.45% | -1,340.68% | -153.46% | -113.83% | -2,150.61% | -1,307.57% | -827.94% | 0.00% |
| Total Other Income/Expenses | 32.66M | 10.78M | -56.97M | -6.87M | -17.76M | -5.58M | 851.00K | -1.74M | -1.72M | 589.00K | -232.00K | -2.35M | -1.02M | -9.72M | -12.00K | -2.42M | 2.45M | 3.19M | 1.94M | 889.00K | -274.00K | 0.00 | 19.53M | 0.00 |
| Income Before Tax | -4.37M | 294.30M | 77.52M | -75.24M | -152.60M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -18.04M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1.88% | 40.72% | 17.64% | -161.63% | -433.29% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,183.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.02M | 1.14M | 808.00K | 16.54M | -1.20M | 3.76M | 1.45M | -3.01M | -476.00K | -936.00K | -116.00K | 851.00K | 1.02M | 9.72M | 0.00 | -3.29M | 372.00K | -8.75M | 0.00 | 0.00 | -686.00K | -621.00K | 18.41M | 17.06M |
| Net Income | -6.39M | 293.16M | 76.71M | -91.78M | -151.40M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -17.35M | -18.04M | -18.41M | -26.72M |
| Net Income Ratio | -2.75% | 40.56% | 17.46% | -197.15% | -429.87% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,100.73% | -1,264.05% | -780.50% | 0.00% |
| EPS | -0.05 | 2.32 | 0.62 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.88 | -106.04 | -122.91 | -225.90 |
| EPS Diluted | -0.05 | 1.97 | 0.54 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.24 | -106.04 | -122.91 | -225.90 |
| Weighted Avg Shares Out | 128.73M | 126.40M | 116.26M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 179.10K | 170.10K | 149.80K | 118.30K |
| Weighted Avg Shares Out (Dil) | 128.73M | 150.80M | 133.01M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 180.30K | 170.10K | 149.80K | 118.30K |
Dynavax Reports First Quarter 2023 Financial Results
HEPLISAV-B ® vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023 Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47% Strengthened balance...
The Top 7 Growth Stocks in Biotech
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
Saint - Herblain ( France), March 2 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced additional data from remaining clinical studies and an update on regulatory submissions for its inactivated...
Dynavax to Present at the Cowen 43rd Annual Health Care Conference
EMERYVILLE, Calif. , March 1, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Kelly MacDonald, Chief Financial Officer, will participate in a fireside chat at the Cowen 43rd Annual Health...
Dynavax Announces Great Britain Marketing Authorization for HEPLISAV B®, a Two-Dose Adult Hepatitis B Adjuvanted Vaccine
HEPLISAV B is the only two-dose adult hepatitis B vaccine offering protection in just one month EMERYVILLE, Calif. , Feb. 28, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing innovative vaccines, today...
Dynavax Technologies Corporation (DVAX) Q4 2022 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2022 Results Conference Call February 23, 2023 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP, Commercial Rob Janssen - Chief Medical Officer Kelly...
Dynavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Financial Guidance
2022 total revenue of $723 million, up 64% from $439 million in 2021 HEPLISAV-B ® vaccine net product revenue of $126 million, representing 104% growth compared to 2021 CpG 1018® adjuvant vaccine net product revenue of $588 million 2023 HEPLISAV-B...
Dynavax Technologies (DVAX) Upgraded to Strong Buy: Here's What You Should Know
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Dynavax Announces Uplisting to the Nasdaq Global Select Market
EMERYVILLE, Calif. , Jan. 31, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, today announced that effective as of market open today, January 31, 2023, its common stock...
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
-- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG...
Source: https://incomestatements.info
Category: Stock Reports